Clinical Trials Logo

Hemoglobinopathies clinical trials

View clinical trials related to Hemoglobinopathies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06363760 Not yet recruiting - Sickle Cell Disease Clinical Trials

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Start date: June 4, 2024
Phase:
Study type: Observational

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

NCT ID: NCT05586932 Not yet recruiting - Clinical trials for Oxidative Stress in Patient With Haemoglobinopathy and Affect it of Endocrine System

Oxidative Stress and Iron Overload in Patient With Abnormal Haemoglobinopathy

Start date: December 1, 2022
Phase:
Study type: Observational

The effects of iron overload and oxidative stress and dyslipidemia on glucose level and thyroid function in patients with abnormal hemoglobinopathy. 2- Evaluation of MDA level as a marker of oxidative stress.

NCT ID: NCT05184647 Not yet recruiting - Splenectomy; Status Clinical Trials

Total Splenectomy vs Partial Splenectomy in Non-malignant Hemoglobinopathies : Study Comparing the Effectiveness

Start date: January 16, 2022
Phase:
Study type: Observational

Partial splenectomy or total splenectomy are the two surgical treatment of non-malignant hemoglobinoptahie. The aim of this treatment is to decrease transfusion. The main risk is infectious in total splenectomy, that's why partial splenectomy was suggest. But the efficiency of partial splenectomy decrease over time and a totalisation could be mandatory.

NCT ID: NCT04798157 Not yet recruiting - Hemoglobinopathies Clinical Trials

Transcranial Doppler in Children With Hemoglobinopathies

Start date: April 2021
Phase: N/A
Study type: Interventional

Transcranial Doppler ultrasonography (TCD) is a noninvasive, portable technique for evaluating the intracranial vasculature. TCD ultrasonography is performed placing a low frequency (≤ 2 MHz) transducer on the scalp of the patient, in order to visualize the intracranial arterial vessels through specific acoustic windows, where bone is thinner, and evaluate cerebral blood flow velocity (CBFV) . Patients diagnosed to have hemoglobinopathy conditions with its most common forms thalassemia and sickle cell disease manifest both biochemical and clinical evidence of hypercoagulability conditions include deep venous thrombosis, pulmonary emboli and recurrent arterial occlusion . Cerebrovascular accidents can be identified using transcranial Doppler ultrasonography which enables evaluation of cerebral artery blood flow velocity with a sensitivity of 90% and specificity of 100 % when compared with cerebral angiography . According to the stroke prevention trial in sickle cell anemia (STOP) study ,TCDs were classified based on blood velocity in the circle of Willis, expressed as time averaged mean of the maximum velocity (TAMMV). Children with abnormal, high velocities (>200cm/s) were at increased risk of stroke, which was reduced by 90% after starting regular blood transfusions. TAMMVs less than 170cm/s were classified as normal with annual TCD scanning recommended, whereas velocities between 170 and 200cm/s were called conditional, and followed up more closely without starting transfusion.